Santo Domingo · Dominican Republic
Foundational science, engineered for deployment
Four platforms in fields where incremental improvement is no longer enough: how bacterial infection is controlled, how proteins are purified, how agricultural waste becomes fuel, and how mass is moved against gravity.
Four technologies, one mission
Sustainable innovation across health, food, energy, and mobility
01 / Energy & Mobility
Gravity, Reimagined
Patent-pending laser-based gravitational field modulation, in development for levitating transport, clean energy lift, and aerospace propulsion.
Gravity-Modulating Laser Technology →02 / Biotech
Purity at Scale
A single-step chromatography protocol at 23-fold purification, on the FPLC and HPLC infrastructure producers already own.
Proprietary Protein Purification Protocol →03 / Health
Post-Antibiotic Protection
Lysozyme, chelation and a pH-stabilized formulation that kills bacteria without applying the selective pressure that breeds resistance. Clinically validated in humans for dental use; patented in Japan and Mexico.
Universal Bactericide →04 / Biofuel
Waste Into Fuel
Enzymatic hydrolysis that turns corncob, bagasse and agricultural residue into fermentable sugars in under four hours, with the lignin recovered as fuel.
CS-Ethanol Technology →The mechanism
Why resistance does not develop
Antibiotics interfere with a metabolic pathway, so any mutation that routes around that pathway survives and propagates. This platform does not compete with bacterial metabolism at all.
- The chelating agent strips the divalent cations that hold the gram-negative outer membrane together.
- That exposes the peptidoglycan layer normally shielded from enzymatic attack.
- Lysozyme cleaves the peptidoglycan directly, and the cell fails structurally.
- The pH-stabilizing salt keeps the system active under physiological conditions.
Clinical evidence · dental indication
Measured against the reference antiseptic
A comparative study of 70 subjects, included in patent MX 433331, set the experimental formulation against chlorhexidine 0.12%.
Unpleasant taste was reported by 14% in the extraction group, against 88% for chlorhexidine. Taste perception was unaltered in 0% of experimental cases.Comparative clinical study · n=70 · patent MX 433331
The founder
Dr. Diógenes Aybar
Member of the Academia de Ciencias de la República Dominicana, and the named inventor on every granted and pending patent in the portfolio. His work spans enzymology and protein chemistry, where the Aybar Protocol originated, and theoretical physics, where the EMG Theory of the Photon originated.
The theory was published in 1992. The company exists to carry it, and the chemistry that came with it, into the hands of people who can build with it.
- 1992EMG Theory of the Photon published
- 2Patents granted, Mexico and Japan
- 3Platforms in active development
Licensing & partnerships
Work with us on what comes next
Aybar Ecotechnologies works through licensing, joint ventures, and equity structures. Request the investor brief for a specific platform, or schedule a technical demonstration with our research team.